Provided By GlobeNewswire
Last update: Dec 20, 2023
Study results published in Acta Neuropathologica Communications support targeting of RACK1 as a potential therapeutic approach for Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Lobar Degeneration (FTLD).
NASDAQ:PMN (5/1/2025, 9:25:12 PM)
0.65
+0.03 (+4.86%)
Find more stocks in the Stock Screener